125 related articles for article (PubMed ID: 38646859)
1. Evaluation of clinical response and prognostic factors in canine multicentric lymphoma treated with first rescue therapy.
Blaxill JE; Bennett PF
Vet Comp Oncol; 2024 Jun; 22(2):265-277. PubMed ID: 38646859
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
Davies O; Szladovits B; Polton G; Garden OA; Leo C; Lara-Garcia A
Vet Comp Oncol; 2018 Jun; 16(2):276-287. PubMed ID: 29271043
[TBL] [Abstract][Full Text] [Related]
4. Maintenance treatment in relapsed canine lymphoma after a short L-CHOP protocol.
Troedson K; Ignatenko N; Fejos C; Zablotski Y; Hirschberger J
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2021 Jun; 49(3):185-194. PubMed ID: 34157760
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Curran K; Thamm DH
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Tanis JB; Mason SL; Maddox TW; Blackwood L; Killick DR; Amores-Fuster I; Harper A; Finotello R
Vet Comp Oncol; 2018 Sep; 16(3):361-369. PubMed ID: 29380942
[TBL] [Abstract][Full Text] [Related]
7. Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
Wang SL; Lee JJ; Liao AT
Vet J; 2016 Jul; 213():87-9. PubMed ID: 27240922
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Saba CF; Hafeman SD; Vail DM; Thamm DH
J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
[TBL] [Abstract][Full Text] [Related]
9. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH
J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
Burton JH; Garrett-Mayer E; Thamm DH
Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
[TBL] [Abstract][Full Text] [Related]
11. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma.
Lautscham EM; Kessler M; Ernst T; Willimzig L; Neiger R
Vet Rec; 2017 Mar; 180(12):303. PubMed ID: 28100766
[TBL] [Abstract][Full Text] [Related]
13. Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.
Blaxill J; Buzzacott P; Finlay J
Vet Comp Oncol; 2022 Mar; 20(1):215-226. PubMed ID: 34464024
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.
Elliott JW; Cripps P; Marrington AM; Grant IA; Blackwood L
Vet Comp Oncol; 2013 Sep; 11(3):185-98. PubMed ID: 22372620
[TBL] [Abstract][Full Text] [Related]
15. Prednisolone inclusion in a first-line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results.
Zandvliet M; Rutteman GR; Teske E
Vet J; 2013 Sep; 197(3):656-61. PubMed ID: 23746872
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
Treggiari E; Elliott JW; Baines SJ; Blackwood L
Vet Comp Oncol; 2018 Jun; 16(2):194-201. PubMed ID: 28766920
[TBL] [Abstract][Full Text] [Related]
17. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).
Lenz JA; Robat CS; Stein TJ
J Small Anim Pract; 2016 Aug; 57(8):429-34. PubMed ID: 27251593
[TBL] [Abstract][Full Text] [Related]
18. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
[TBL] [Abstract][Full Text] [Related]
19. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]